secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001213900-25-050060
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt reiterates Sept 2025 close target for Evofem deal; Evofem had $19.5M revenue, first ex-US deal signed
--------------------------------------------------------------------------------

- Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.
- Evofem generated $19.5M net revenue last year; has two FDA-approved products (Phexxi, Solosec) and signed first ex-US deal with Pharma 1 in Middle East.
- New manufacturer Lee Pharma committed to lowering Evofem's COGS by over 50% to mitigate tariff volatility and support European expansion.
- Pearsanta's endometriosis/ovarian cancer diagnostic platform expected near revenue in Q4 2025; Adimune autoimmune program targets regulatory filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/0001213900-25-050060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/ea0244325-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer